青霉素过敏患者幽门螺杆菌简化治疗:伏诺拉生-四环素双联疗法的随机对照试验
该随机对照试验纳入300例青霉素过敏的幽门螺杆菌感染初治成人,1:1分组接受伏诺拉生-四环素(VT)双联疗法或铋剂四联疗法(BQT)治疗14天。VT组根除率在意向性分析中为92.0%(138/150),BQT组为89.3%(134/150),达到非劣效;VT组治疗中出现的不良事件发生率显著低于BQT组(14.0% vs 48.0%,p=0.000)。
要点
- VT双联疗法根除率在意向性分析中为92.0%,BQT组为89.3%,达到非劣效。
- VT组治疗中出现的不良事件发生率为14.0%,显著低于BQT组的48.0%(p=0.000)。
- VT组因不良事件停药率为2.0%,低于BQT组的8.7%(p=0.010)。
核心结论
- VT双联疗法作为青霉素过敏人群幽门螺杆菌感染的一线治疗显示出疗效和安全性,与BQT相比疗效相当且治疗中出现的不良事件发生率更低。
研究设计与样本
- 随机对照试验,纳入300例青霉素过敏的幽门螺杆菌感染初治成人,1:1随机接受开放标签VT双联疗法(伏诺拉生20 mg每日两次+四环素500 mg每日三次)或BQT(兰索拉唑30 mg每日两次+胶体铋150 mg每日三次+四环素500 mg每日三次+甲硝唑400 mg每日三次),疗程14天。
- 主要结局为VT双联组与BQT组根除率的非劣效性,次要结局包括不良反应评估。
主要发现
- 意向性分析根除率:VT组92.0%(138/150,95%CI 86.1%至95.6%),BQT组89.3%(134/150,95%CI 83.0%至93.6%),差值2.7%(95%CI -4.6%至10.0%),非劣效性p=0.000。
- 改良意向性分析根除率:VT组94.5%(138/146,95%CI 89.1%至97.4%),BQT组93.1%(134/144,95%CI 87.3%至96.4%),差值1.5%(95%CI -4.9%至8.0%),非劣效性p=0.001。
- 符合方案分析根除率:VT组95.1%(135/142,95%CI 89.7%至97.8%),BQT组97.7%(128/131,95%CI 92.9%至99.4%),差值2.6%(95%CI -2.9%至8.3%),非劣效性p=0.000。
- 治疗中出现的不良事件发生率VT组14.0%,BQT组48.0%,p=0.000;因不良事件停药率VT组2.0%,BQT组8.7%,p=0.010。
关键数值与推荐
- VT双联疗法方案:伏诺拉生20 mg每日两次+四环素500 mg每日三次,疗程14天。
- BQT方案:兰索拉唑30 mg每日两次+胶体铋150 mg每日三次+四环素500 mg每日三次+甲硝唑400 mg每日三次,疗程14天。
临床怎么用
- 作者认为,VT双联疗法可作为青霉素过敏人群幽门螺杆菌感染的一线治疗,疗效与BQT相当且治疗中出现的不良事件发生率更低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: This study aimed to evaluate the efficacy and safety of vonoprazan and tetracycline (VT) dual therapy as first-line treatment for Helicobacter pylori infection in patients with penicillin allergy. METHODS: In this randomised controlled trial, treatment-naïve adults with H. pylori infection and penicillin allergy were randomised 1:1 to receive either open-label VT dual therapy (vonoprazan 20 mg two times per day+tetracycline 500 mg three times a day) or bismuth quadruple therapy (BQT; lansoprazole 30 mg two times per day+colloidal bismuth 150 mg three times a day+tetracycline 500 mg three times a day+metronidazole 400 mg three times a day) for 14 days. The primary outcome was non-inferiority in eradication rates in the VT dual group compared with the BQT group. Secondary outcomes included assessing adverse effects. RESULTS: 300 patients were randomised. The eradication rates in the VT group and the BQT group were: 92.0% (138/150, 95% CI 86.1% to 95.6%) and 89.3% (134/150, 95% CI 83.0% to 93.6%) in intention-to-treat analysis (difference 2.7%; 95% CI -4.6% to 10.0%; non-inferiority p=0.000); 94.5% (138/146, 95% CI 89.1% to 97.4%) and 93.1% (134/144, 95% CI 87.3% to 96.4%) in modified intention-to-treat analysis (difference 1.5%; 95% CI -4.9% to 8.0%; non-inferiority p=0.001); 95.1% (135/142, 95% CI 89.7% to 97.8%) and 97.7% (128/131, 95% CI 92.9% to 99.4%) in per-protocol analysis (difference 2.6%; 95% CI -2.9% to 8.3%; non-inferiority p=0.000). The treatment-emergent adverse events (TEAEs) were significantly lower in the VT group (14.0% vs 48.0%, p=0.000), with fewer treatment discontinuations due to TEAEs (2.0% vs 8.7%, p=0.010). CONCLUSIONS: VT dual therapy demonstrated efficacy and safety as a first-line treatment for H. pylori infection in the penicillin-allergic population, with comparable efficacy and a lower incidence of TEAEs compared with traditional BQT. TRIAL REGISTRATION NUMBER: ChiCTR2300074693.
引用
- Gao W, Liu J, Wang X, et al. Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy. Gut. 2024. PMID: 38906695. doi:10.1136/gutjnl-2024-332640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。